In direct compression operations where veterinary oral tablets are manufactured at active loadings below 5% w/w, sodium cromoglicate is handled as a white to off-white hygroscopic powder with poor flow and a tendency to consolidate during storage. Weighing and dispensing should be confined to a dehumidified suite maintained below 40% RH, because surface moisture adsorption on the API is a primary contributor to punch face picking on rotary tablet presses. A standard production sequence begins with sieving the API through a 500 µm stainless steel mesh and combining it with an equal mass of pre-sieved lactose monohydrate or microcrystalline cellulose in a geometric dilution before transfer to a low-shear bin blender. Blend uniformity is monitored by sampling at 10 positions and comparing assay variability against the finished product uniformity requirements of USP <905> and Ph. Eur. 2.9.40; a final blend RSD below 5% is commonly targeted, while the dosage unit acceptance value is held at ≤15. Sodium starch glycolate at 2%–4% w/w and crospovidone at 2%–3% w/w are added before lubrication, and magnesium stearate is limited to 0.5%–0.75% w/w because higher concentrations reduce tablet breaking force under USP <1217>. Compression runs on a force-feeder rotary press with 8 mm round tooling show that dwell-time adjustment is necessary when blend bulk density falls below 0.45 g/cm³, otherwise pre-compression capping becomes intermittent. Tablet friability is assessed by USP <1216>, and dissolution is evaluated according to USP <711> with a product-specific method that must be validated against the finished veterinary tablet formulation.

Why Does Aqueous Granulation Depress Content Uniformity Below 2% w/w Active Loading?

At active loadings below 2% w/w, aqueous high-shear granulation introduces a process conflict that is not observed with dry blending: the water-soluble API dissolves in the binder fluid and migrates to granule surfaces during drying. If an aqueous binder based on povidone K30 is added to a granulator bowl containing the API-excipient dry mix, dissolved sodium cromoglicate is carried toward evaporation sites on the outer granule layer, producing intergranule assay variation that cannot be corrected by prolonged final blending. Batch records from production-scale high-shear mixers with torque endpoint control indicate that the granulation endpoint should be determined by impeller power consumption rather than by fixed time, because over-granulation increases the fraction of dense, API-depleted cores. The wet mass is discharged through a 1.0 mm screen and dried in a fluid-bed dryer with inlet air temperature held at 50–60°C until loss on drying by Ph. Eur. 2.2.32 reaches 1.5%–2.5% w/w. Granules above 3.5% w/w moisture exhibit punch adhesion during compression, while granules below 1.5% w/w produce friable tablets because microcrystalline cellulose loses plastic deformation capacity at very low moisture. Crospovidone at 4% w/w and croscarmellose sodium at 2% w/w are incorporated after drying to avoid premature swelling in the binder phase. The final granular blend is compressed on a rotary press equipped with in-process die table analysis; tablets are sampled according to USP <905> and dissolution is measured by USP <711>. Because published thermal degradation data for this veterinary-grade API in the specific granulated configuration may be limited, a forced degradation study under VICH GL18 stress conditions is required before drying parameters are fixed for commercial batches.

When the Blend Is Filled Into Hard Gelatin Capsules Below 40% RH

When the final blend is intended for hard gelatin capsules, the primary process variable is the moisture equilibrium between the hygroscopic API and the capsule shell. A filling suite held below 40% RH is used to minimize shell softening, but over-drying below 30% RH increases triboelectric charging of the low-bulk-density powder on tamping-pin capsule fillers. The API is pre-dried to a loss on drying of 1.0%–2.0% w/w before blending with lactose monohydrate and microcrystalline cellulose; the powder blend is then compacted in a roller compactor and sieved to 0.8 mm to produce granules with a Carr Index below 25, which is required to maintain fill weight drift within ±5% on a tamping-pin machine. Capsule fill weight uniformity is assessed by USP <905>, and the dissolution test is carried out with USP <711> after method validation, because gelatin shell cross-linking under humidity stress can retard release in the dissolution vessel. Batch records show that static charge accumulation on dosator nozzles is the main source of intermittent under-filling when the API fraction exceeds 10% w/w and the excipient is predominantly microcrystalline cellulose; adding 0.5% w/w colloidal silicon dioxide and reducing dosator speed below the maximum machine setting returns fill variation to an acceptable range. The filled capsules are packaged in HDPE bottles with desiccant and stored at 25°C/60% RH or under conditions established by VICH GL18, because moisture uptake above 60% RH can deform the shell and initiate cap separation during distribution.

Because the injectable route requires a sterile, non-pyrogenic solution, sodium cromoglicate veterinary grade is dissolved in Water for Injection at the assigned concentration and sterilised by filtration rather than by a default terminal steam cycle. A 0.22 µm membrane filter is selected after compatibility screening with the final solution pH, because filter extractables and API binding to polyvinylidene fluoride or polyethersulfone membranes can reduce recovery at low concentration. The pH is adjusted with dilute sodium hydroxide or hydrochloric acid to a defined value; formulation development must establish the stable pH range and demonstrate that the chosen pH remains within specification through the assigned shelf life under VICH GL18. Osmolality is measured by USP <785> or Ph. Eur. 2.2.35, and the composition is adjusted with sodium chloride to the labelled osmolality; where tonicity adjustment is not required, the lower osmolality must be justified against the intended veterinary route. After sterile filtration, the solution is filled into depyrogenated Type I glass vials under Grade A conditions and stoppered; sterility testing follows USP <71> or Ph. Eur. 2.6.1, while bacterial endotoxin testing follows USP <85> or Ph. Eur. 2.6.14. Particulate matter is limited by USP <788> or Ph. Eur. 2.9.19. Published terminal sterilisation data for this veterinary configuration may be limited, so the manufacturer cannot assume that a 121°C cycle is valid without a controlled heat-exposure study; until such data are generated, aseptic filtration remains the conservative process design.

Oral Powder Sachet Fill Weight Drift Is Controlled by Auger Hopper Head Pressure

A single-dose oral powder places the API in direct contact with a flavour-masked carrier, and the filling operation is dominated by the need to maintain strict mass uniformity in low-weight sachets. Sodium cromoglicate is mixed with sucrose or mannitol and a desiccant-stabilised mineral filler in a tumble blender; all components are sieved through a 500 µm mesh before blending. The final powder is filled on a vertical auger filler into laminate sachets constructed from polyethylene, aluminium foil, and polyester, with the aluminium layer acting as the primary moisture barrier. Fill weight variation is evaluated under Ph. Eur. 2.9.5 for single-dose powders or the corresponding USP mass variation chapter, and loss on drying is controlled below 2.0% w/w by Ph. Eur. 2.2.32. In production batches, fill weight drift above ±5% is most often traced to powder densification in the hopper rather than to auger calibration; vibratory densification at the hopper outlet creates a denser powder bed that delivers more mass per flight. Process engineers counteract this by installing a low-shear agitator or maintaining the hopper fill volume below 50%, because powder head pressure directly controls auger fill density. Dissolution of the reconstituted powder is evaluated after dispersion in water at 37°C using USP <711> apparatus as the equipment basis; acceptance criteria are formulation-specific and must be justified against bioavailability data for the target veterinary species. Storage stability is assigned under VICH GL18 conditions, and the desiccant-to-fill ratio is fixed after moisture gain studies at 25°C/60% RH.

In dry granulation, the hygroscopic API is pre-blended with excipients and densified on a roller compactor instead of being exposed to aqueous granulation. This route is selected when a wet-granulated batch shows API migration or when the final dosage form is a granule filled into sachets, because dry powder layering avoids dissolution-mediated redistribution that creates content uniformity drift. The API and excipients are pre-blended in a bin blender, then compacted at roll pressures sufficient to form ribbons; the ribbons are milled through a 0.8 mm screen and the resulting granules are classified. Fine fractions below 150 µm are recycled into the compactor, but the recycle ratio is capped to avoid an increase in work-hardened particles that resist disintegration and slow dissolution. Granule moisture is held below 2.0% w/w by Ph. Eur. 2.2.32, and the final blend is tested for bulk density and flow. Particle size distribution of the milled granules is measured by laser diffraction according to ISO 13320 for batch-to-batch comparison. In production-scale roller compactors, the main failure mode is non-uniform ribbon density across the roller width due to insufficient de-aeration in the feed screw; this creates hard granules on the outer edges and weak cores in the center. Equipment operators adjust vacuum de-aeration and roll gap rather than relying solely on roll pressure, because roll pressure alone does not compensate for uneven material feed. The granules are then filled into sachets or capsules and tested for content uniformity under USP <905> or mass uniformity under Ph. Eur. 2.9.5 as appropriate.

Premix Homogeneity and Carryover Limits in Medicated Feed Lines

In medicated feed applications where sodium cromoglicate is incorporated into a premix, the pharmaceutical solid-dosage logic of dose-unit uniformity is replaced by the requirement for homogeneous distribution in a carrier that will be further diluted at the feed mill. The EU medicated feed framework under EU 2019/4 and the corresponding US current good manufacturing practice under 21 CFR 225.1 require equipment design and cleaning documentation that control carryover from one production run to the next. A typical premix is prepared by pre-blending the API with a small portion of calcium carbonate or lactose monohydrate in a geometric dilution, sieving through a 500 µm screen, and then transferring the mixture to a ribbon mixer. Sampling at 10 defined positions after a fixed mixing time is used to calculate the coefficient of variation; premix release is only justified when the CV remains below 10%, though the exact limit must be confirmed against the intended feed incorporation rate. Field inspection of ribbon mixers reveals that dead zones behind the discharge gate and along the shaft seals retain API-rich material, producing batch-to-batch drift unless the mixer is dismantled during cleaning. Carrier particle size and moisture content influence segregation; carriers with a mean particle size below 150 µm tend to adhere to mixer walls and increase carryover, while carriers above 800 µm can segregate from the fine API during transfer. The cleaned equipment is verified by swab or rinse sampling, and the analytical method is validated for recovery and precision before routine release. Published data for sodium cromoglicate carryover in specific feed mill configurations is limited, so the operator must generate recovery data on the actual mixer and conveyor line rather than relying on platform-wide assumptions.

Preservative Efficacy Is Tested Under USP <51> and Ph. Eur. 5.1.3

An oral solution requires a buffer system that maintains the API in solution without exceeding the solubility of a preservative or altering the formulation pH beyond the verified stability range. Sodium cromoglicate is dissolved in purified water, and the pH is adjusted with a dilute acid or base to a value selected from the forced degradation profile rather than from a default compendial value. The preservative system, whether methylparaben, propylparaben, or potassium sorbate, is evaluated for antimicrobial effectiveness according to USP <51> and Ph. Eur. 5.1.3; acceptance criteria depend on the intended closure and the dosing period of the multi-dose container. Buffering is required because carbon dioxide uptake in an unbuffered solution can produce pH drift that affects the ionisation state of the API and the chemical stability of the preservative. The solution is protected from light by packaging in amber glass or an opaque high-density polyethylene bottle, and the container-closure system is subjected to a water vapour transmission test and a child-resistant closure function test before stability loading. Dissolved oxygen is reduced by nitrogen sparging where forced degradation data show oxidation sensitivity; if no oxidation pathway is observed, sparging is not required and should not be added as a routine step. During process scale-up, the mixing vessel is charged with water first, the API is added slowly under low-shear agitation, and the solution is filtered through a 0.45 µm polishing filter before filling. The filled solution is tested for assay, pH, preservative content, and microbial limits; storage conditions are assigned under VICH GL18 and supported by long-term, intermediate, and accelerated stability stations. Published data for this specific veterinary oral solution configuration is limited, so the formulator must conduct preservative challenge and pH excursion studies on the actual formulation rather than transferring data from a different dosage form.